KR102123645B1 - Cosmetic composition with Angelica japonica extract - Google Patents
Cosmetic composition with Angelica japonica extract Download PDFInfo
- Publication number
- KR102123645B1 KR102123645B1 KR1020190131636A KR20190131636A KR102123645B1 KR 102123645 B1 KR102123645 B1 KR 102123645B1 KR 1020190131636 A KR1020190131636 A KR 1020190131636A KR 20190131636 A KR20190131636 A KR 20190131636A KR 102123645 B1 KR102123645 B1 KR 102123645B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- cosmetic composition
- skin
- fine dust
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- 239000002537 cosmetic Substances 0.000 title claims abstract description 50
- 241000092897 Angelica japonica Species 0.000 title claims description 9
- 239000000284 extract Substances 0.000 title abstract description 62
- 230000008591 skin barrier function Effects 0.000 claims abstract description 20
- 230000037303 wrinkles Effects 0.000 claims abstract description 17
- 238000005728 strengthening Methods 0.000 claims abstract description 9
- 239000000428 dust Substances 0.000 claims description 41
- 108010045583 Desmoglein 2 Proteins 0.000 claims description 11
- 102000005707 Desmoglein 2 Human genes 0.000 claims description 11
- 102000004162 Claudin-1 Human genes 0.000 claims description 10
- 108090000600 Claudin-1 Proteins 0.000 claims description 10
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 claims description 10
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 230000002829 reductive effect Effects 0.000 claims description 6
- 230000001965 increasing effect Effects 0.000 claims description 5
- 239000000469 ethanolic extract Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 1
- 230000008961 swelling Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 34
- 230000003078 antioxidant effect Effects 0.000 abstract description 13
- 206010040880 Skin irritation Diseases 0.000 abstract description 12
- 230000036556 skin irritation Effects 0.000 abstract description 12
- 231100000475 skin irritation Toxicity 0.000 abstract description 12
- 239000003963 antioxidant agent Substances 0.000 abstract description 9
- 230000006872 improvement Effects 0.000 abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 49
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 20
- 210000003491 skin Anatomy 0.000 description 20
- 102000004169 proteins and genes Human genes 0.000 description 19
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 238000009472 formulation Methods 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 12
- 238000002835 absorbance Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 11
- 239000000499 gel Substances 0.000 description 11
- 229940040511 liver extract Drugs 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 230000009759 skin aging Effects 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- -1 blockers Substances 0.000 description 9
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- 238000012790 confirmation Methods 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000006180 TBST buffer Substances 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000000344 soap Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 230000036542 oxidative stress Effects 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229910002091 carbon monoxide Inorganic materials 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 4
- 230000007760 free radical scavenging Effects 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 244000144972 livestock Species 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 101150095408 CNMD gene Proteins 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 102000004890 Interleukin-8 Human genes 0.000 description 3
- 108090001007 Interleukin-8 Proteins 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 3
- 239000008004 cell lysis buffer Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- 108700032225 Antioxidant Response Elements Proteins 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 102000002029 Claudin Human genes 0.000 description 2
- 108050009302 Claudin Proteins 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- 108010071382 NF-E2-Related Factor 2 Proteins 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000002803 fossil fuel Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 231100000544 menstrual irregularity Toxicity 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N nordihydroguaiaretic acid Chemical compound C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 갯강활추출물을 함유하는 화장료 조성물에 관한 것으로, 항산화, 피부장벽강화, 피부자극완화, 피부주름개선 효과가 있는 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition containing a Gaetgang extract, and relates to a cosmetic composition having antioxidant, skin barrier strengthening, skin irritation relaxation, and skin wrinkle improvement effects.
Description
본 발명은 갯강활추출물을 함유하는 화장료 조성물에 관한 것으로, 항산화, 피부장벽강화, 피부자극완화 효과가 있는 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition containing a Gaetgang Liver Extract, and relates to a cosmetic composition having antioxidant, skin barrier strengthening, and skin irritation alleviating effects.
미세먼지는 우리 눈에 보이지 않는 아주 작은 물질로 대기 중에 오래 떠다니거나 흩날리는 직경 10㎛ 이하의 입자상 물질을 말한다. 미세먼지는 황사와 달리 공장 등에서 사용하는 화석연료에 의한 인위적인 오염물질로 질산염(NO3-), 암모늄(NH4 +), 황산염(SO4 2-) 등의 이온 성분과 탄소화합물, 금속화합물 등으로 이루어져 있다. 장기간 미세먼지에 노출될 경우 면역력이 급격히 저하되어 감기, 천식, 기관지염 등의 호흡기 질환은 물론 심혈관질환, 피부질환, 안구질환 등 각종 질병에 노출될 수 있다. 특히 직경 2.5㎛ 이하의 초미세먼지는 인체 내 기관지 및 폐 깊숙한 곳까지 침투하여 각종 질환을 유발하기 쉽다.Fine dust is a very small material that is invisible to our eyes, and refers to a particulate matter with a diameter of 10 µm or less that floats or floats in the air for a long time. Fine dust is an artificial contaminant by fossil fuels used in factories, unlike yellow dust. It is composed of ionic components such as nitrate (NO3-), ammonium (NH 4 + ) and sulfate (SO 4 2- ), carbon compounds, and metal compounds consist of. When exposed to fine dust for a long period of time, immunity rapidly decreases, which can lead to exposure to various diseases such as cardiovascular disease, skin disease, and eye disease, as well as respiratory diseases such as cold, asthma, and bronchitis. In particular, ultra-fine dust having a diameter of 2.5 µm or less can easily penetrate into the human bronchi and deep into the lungs and cause various diseases.
미세먼지는 건선, 아토피성 피부염, 여드름과 같은 염증성 피부질환뿐 아니라 피부노화, 탈모, 피부암에도 영향을 미친다. 미세먼지는 모공의 크기보다 최대 20 정도 작기 때문에 피부 내로 쉽게 침투할 수 있으며, 피부의 유분과 엉겨붙으면서 노폐물이 쌓여 피부 장벽을 무너뜨리고 모공 속에 비소, 카드뮴, 납 등 금속 유해물질이 유입되어 피부 트러블 또는 염증 반응의 원인이 된다. 이에 따라 피부 면역 기능이 약화되고, 피부장벽의 보호기능이 상실되며 심각한 피부 질병을 초래할 수 있다. 또한 미세먼지에 의한 염증성 사이토카인 증가와 체내 활성산소의 증가는 피부 세포에서 염증 반응, 주름 생성, 피부 가려움증을 증가시키며 심각하게는 피부암 발병에도 영향을 준다고 알려져 있다.Fine dust affects not only inflammatory skin diseases such as psoriasis, atopic dermatitis, and acne, but also skin aging, hair loss, and skin cancer. Since the fine dust is up to 20 smaller than the size of the pores, it can easily penetrate into the skin, and as the oils and entanglements of the skin accumulate, the skin barrier breaks down and metal harmful substances such as arsenic, cadmium, and lead are introduced into the skin. It can cause trouble or inflammatory reaction. Accordingly, the skin immune function is weakened, the protective function of the skin barrier is lost, and serious skin disease may be caused. It is also known that increased inflammatory cytokines caused by fine dust and increased free radicals in the body increase the inflammatory response, wrinkle formation, and itching in skin cells, and seriously affect the development of skin cancer.
본 발명은 미세먼지로부터 유발되는 피부 노화, 피부 자극 등을 완화할 수 있는 화장료 조성물을 개발하여 제공하고자 한다.The present invention is to develop and provide a cosmetic composition capable of alleviating skin aging and skin irritation caused by fine dust.
본 발명은 갯강활(Angelica japonica)추출물을 함유하는 피부노화개선용 화장료 조성물을 제공한다.The present invention provides a cosmetic composition for improving skin aging containing an extract of Angelica japonica.
본 발명에 있어서, 상기 피부노화는 바람직하게는 미세먼지로 말미암은 것일 수 있다.In the present invention, the skin aging may preferably be due to fine dust.
또한, 본 발명은 갯강활(Angelica japonica)추출물을 함유하는 피부장벽강화용 화장료 조성물을 제공한다.In addition, the present invention provides a cosmetic composition for strengthening the skin barrier containing an extract of Angelica japonica.
본 발명에 있어서, 상기 피부장벽은 바람직하게는 미세먼지로 인하여 손상된 피부장벽일 수 있다.In the present invention, the skin barrier may preferably be a skin barrier damaged due to fine dust.
또한, 본 발명은 갯강활(Angelica japonica)추출물을 함유하는 피부자극완화용 화장료 조성물을 제공한다.In addition, the present invention provides a cosmetic composition for relieving skin irritation containing an extract of Angelica japonica.
본 발명에 있어서, 상기 피부자극은 바람직하게는 미세먼지로 말미암은 것일 수 있다.In the present invention, the skin irritation may be preferably caused by fine dust.
또한, 본 발명은 갯강활(Angelica japonica)추출물을 함유하는 피부주름개선용 화장료 조성물을 제공한다.In addition, the present invention provides a cosmetic composition for improving wrinkles containing an extract of Angelica japonica.
본 발명에 있어서, 상기 피부주름은 바람직하게는 미세먼지로 말미암은 것일 수 있다.In the present invention, the skin wrinkles may preferably be due to fine dust.
본 발명에 있어서, 상기 갯강활추출물은 바람직하게는 물, 탄소수 1-4의 무수 또는 함수 저급 알코올, 프로필렌글리콜, 부틸렌글리콜, 글리세린, 아세톤, 에틸 아세테이트, 클로로포름, 부틸 아세테이트, 디에틸에테르, 디클로로메탄, 헥산 및 이들의 혼합물로 구성된 군으로부터 선택되는 추출용매를 이용하여 수득한 것일 수 있다.In the present invention, the cane extract is preferably water, anhydrous or hydrous lower alcohol having 1 to 4 carbon atoms, propylene glycol, butylene glycol, glycerin, acetone, ethyl acetate, chloroform, butyl acetate, diethyl ether, dichloro It may be obtained using an extraction solvent selected from the group consisting of methane, hexane and mixtures thereof.
본 발명에 있어서, 상기 갯강활추출물은 바람직하게는 화장료 조성물 전체 중량에 대하여 0.001~30 중량%로 함유하는 것이 좋다.In the present invention, it is preferable to contain the cane extract, preferably 0.001 to 30% by weight relative to the total weight of the cosmetic composition.
본 발명의 갯강활추출물은 항산화 효과에 따른 피부 노화 억제 효과가 있으며, 피부장벽강화, 피부주름개선 및 피부자극완화 효과가 있다.The Gaetgang Liver Extract of the present invention has the effect of inhibiting skin aging according to the antioxidant effect, and has the effect of strengthening the skin barrier, improving skin wrinkles and alleviating skin irritation.
본 발명은 갯강활추출물을 함유하며, 항산화, 피부장벽강화, 피부주름개선, 피부자극완화 효과가 있는 화장료 조성물을 제공한다. The present invention provides a cosmetic composition containing a Gaetgang extract, antioxidant, skin barrier strengthening, skin wrinkle improvement, skin irritation relaxation effect.
도 1은 갯강활추출물의 DPPH 라디칼 소거 효과를 나타내는 실험 결과이다.
도 2는 갯강활추출물의 Claudin-1 및 Desmoglein-2 발현 효과를 나타내는 실험 결과이다.
도 3은 갯강활추출물의 Nrf2 발현 효과를 나타내는 실험 결과이다.
도 4는 갯강활추출물의 MMP-1 발현 억제 효과를 나타내는 실험 결과이다.
도 5는 갯강활추출물의 NO 저해율을 나타내는 실험 결과이다.
도 6은 갯강활추출물을 함유하는 화장료 조성물의 TNF-α와 IL-8 발현 억제 효과를 나타내는 실험 결과이다.1 is an experimental result showing the DPPH radical scavenging effect of the Gaetgang livestock extract.
Figure 2 is the experimental results showing the effect of the expression of Claudin-1 and Desmoglein-2 of the Gaetgang live extract.
3 is an experimental result showing the effect of Nrf2 expression of the Gaetgang live extract.
Figure 4 is an experimental result showing the effect of inhibiting the MMP-1 expression of the Gaetgang live extract.
5 is an experimental result showing the NO inhibition rate of the Gaetgang livestock extract.
6 is an experimental result showing the inhibitory effect of TNF-α and IL-8 expression of the cosmetic composition containing the Gaetgang extract.
본 발명은 갯강활(Angelica japonica)추출물을 함유하는 피부노화개선용, 피부장벽강화용, 피부자극완화용, 피부주름개선용 화장료 조성물을 제공한다. 본 발명에 있어서, 상기 피부노화, 피부자극, 피부주름은 바람직하게는 미세먼지로 말미암은 것일 수 있으며, 상기 피부장벽은 미세먼지로 인하여 손상된 피부장벽일 수 있다.The present invention provides a cosmetic composition for improving skin aging, strengthening skin barrier, reducing skin irritation, and improving skin wrinkles, containing an extract of Angelica japonica . In the present invention, the skin aging, skin irritation, and skin wrinkles may preferably be caused by fine dust, and the skin barrier may be a skin barrier damaged by fine dust.
갯강활(Angelica japonica)은 다년초로 줄기의 위쪽에서 가지를 치며 노란빛이 도는 흰색의 즙액이 있고 겉에 어두운 자주색의 줄이 있는 식물이다. 꽃은 흰색으로 7~8월에 피며 바닷가(갯가)에서 잘 자란다. 신체허약, 두통, 월경불순, 복통의 치료제로 사용되기도 한다. Angelica japonica is a perennial plant that branches from the top of the stem and has a yellowish white juice and dark purple stripes on the outside. The flowers are white and bloom in July-August and grow well on the beach. It is also used as a remedy for physical weakness, headache, menstrual irregularities, and abdominal pain.
본 발명에 있어서, 상기 갯강활추출물은, 본 발명이 속하는 기술분야에서 통상적으로 사용되는 다양한 추출 방법을 이용할 수 있으나, 바람직하게는 물, 탄소수 1-4의 무수 또는 함수 저급 알코올, 프로필렌글리콜, 부틸렌글리콜, 글리세린, 아세톤, 에틸 아세테이트, 클로로포름, 부틸 아세테이트, 디에틸에테르, 디클로로메탄, 헥산 및 이들의 혼합물로 구성된 군으로부터 선택되는 추출용매를 이용하여 수득할 수 있다. 더욱 바람직하게는 갯강활 중량 10배의 70%(v/v) 에탄올 수용액을 이용하여 추출하는 것이 좋다. 갯강활추출물을 화장료 조성물로 이용하기 위하여 적절한 용매에 용해하여 사용할 수 있으며, 바람직하게는 정제수, 에탄올, 부틸렌글리콜, 프로필렌글리콜 중에서 선택되는 1종 이상의 용매를 사용하여 분산 및 용해하여 사용하는 것이 좋다. In the present invention, the canine extract, can use a variety of extraction methods commonly used in the art to which the present invention pertains, preferably water, anhydrous or hydrous lower alcohols having 1 to 4 carbon atoms, propylene glycol, butyl It can be obtained using an extraction solvent selected from the group consisting of renglycol, glycerin, acetone, ethyl acetate, chloroform, butyl acetate, diethyl ether, dichloromethane, hexane and mixtures thereof. More preferably, it is preferable to extract using a 70% (v/v) ethanol aqueous solution of 10 times the weight of the gland stick. In order to use the gaet extract, it can be dissolved in an appropriate solvent for use as a cosmetic composition. Preferably, it is preferable to use it by dispersing and dissolving it using one or more solvents selected from purified water, ethanol, butylene glycol, and propylene glycol. .
본 발명의 갯강활추출물은 자유라디칼 소거 효과에 따른 항산화효과가 있으며, 이에 따라 피부 노화 억제 효능이 있는것으로 확인되었다. The Gaetgang Liver Extract of the present invention has an antioxidant effect according to the free radical scavenging effect, and thus it was confirmed that it has the effect of inhibiting skin aging.
또한, 본 발명의 갯강활추출물은 Claudin-1 및 Desmoglein-2의 발현을 촉진시켜 피부장벽강화 효능이 있는 것으로 확인되었다. 피부 장벽을 구성하는 막투과단백질(trans-membrane protein)인 Claudin-1 및 Desmoglein-2은 미세먼지에 의해 발현이 감소하며, 이에 따라 피부장벽이 약화되는 문제가 발생할 수 있으나, 본 발명의 갯강활추출물을 함유하는 화장료 조성물이 미세먼지에 의해 발현이 감소되는 Claudin-1과 Desmoglein-2의 발현을 증가시켜 피부장벽을 강화효과를 발휘하는 것을 확인하였다. In addition, it was confirmed that the intestinal lubricity extract of the present invention promotes the expression of Claudin-1 and Desmoglein-2, thereby enhancing skin barrier. Claudin-1 and Desmoglein-2, which are trans-membrane proteins constituting the skin barrier, have reduced expression due to fine dust, and thus a problem that the skin barrier is weakened may occur, but the intestinal lubrication of the present invention It was confirmed that the cosmetic composition containing the extract exerts a strengthening effect on the skin barrier by increasing the expression of Claudin-1 and Desmoglein-2, whose expression is reduced by fine dust.
또한, 본 발명의 갯강활추출물은 Nrf2 발현을 촉진하여 산화적 스트레스로부터 인체를 보호하고 해독하는 효과가 있음을 확인하였다. In addition, it was confirmed that the gaet gang extract of the present invention has an effect of protecting and detoxifying the human body from oxidative stress by promoting Nrf2 expression.
또한, 본 발명의 갯강활추출물은 MMP-1의 발현을 억제하는 것으로 나타났다. MMP-1은 미세먼지에 의해 발현이 촉진될 수 있으나, 본 발명의 갯강활추출물은 미세먼지에 의해 유발되는 MMP-1의 발현을 효과적으로 억제하며 주름 개선 효능이 있음을 확인하였다. In addition, it was found that the intestinal lubricity extract of the present invention inhibits the expression of MMP-1. MMP-1 can be promoted by fine dust expression, but it was confirmed that the cantilever extract of the present invention effectively suppresses the expression of MMP-1 caused by fine dust and has the effect of improving wrinkles.
또한, 본 발명의 갯강활추출물은 NO 억제 효과에 따른 항산화효과가 있으며, 이에 따라 피부 노화 억제 효능이 있는것으로 확인되었다.In addition, the Gaet ganglung extract of the present invention has an antioxidant effect according to the NO inhibitory effect, and thus it was confirmed that it has the effect of inhibiting skin aging.
한편, 본 발명에 있어서, 상기 갯강활추출물은, 바람직하게는 화장료 조성물 전체 중량에 대하여 0.001~30 중량%로 함유하는 것이 좋다. 0.001 중량% 미만으로 포함되는 경우에는 본 발명에서 확인한 여러 피부 기능성의 발휘 효과가 미미하고, 30.0 중량%를 초과하는 경우에는 재료 투입량 대비 효율성이 떨어져 경제적이지 못하다.On the other hand, in the present invention, it is preferable to contain the cane extract, preferably 0.001 to 30% by weight relative to the total weight of the cosmetic composition. When included in less than 0.001% by weight, the effect of exerting various skin functions confirmed in the present invention is insignificant, and when it exceeds 30.0% by weight, it is not economical because the efficiency is less than the material input.
본 발명의 갯강활추출물을 함유하는 화장료 조성물은 아래 실험에서 보듯이 피부 주름 개선 효과가 있으며, 염증성 사이토카인인 TNF-α와 IL-8의 발현량을 크게 감소시키켜 피부 자극 완화 효과가 있음이 확인되었다. 피부 주름이나 염증성 사이토카인은 미세먼지에 의해 유발될 수 있는데, 본 발명의 갯강활추출물을 함유하는 화장료 조성물은 미세먼지에 의해 유발되는 자극에 대한 완화 효과가 있음을 확인하였다.The cosmetic composition containing the gland extract of the present invention has an effect of improving skin wrinkles, as shown in the experiment below, and has an effect of alleviating skin irritation by significantly reducing the expression levels of the inflammatory cytokines TNF-α and IL-8. Was confirmed. Skin wrinkles or inflammatory cytokines can be caused by fine dust, and it was confirmed that the cosmetic composition containing the cannula extract of the present invention has a relieving effect against irritation caused by fine dust.
한편, 본 발명의 화장료 조성물은, 일 예로, 용액, 현탁액, 유탁액, 페이스트, 화장수, 젤, 수용성 리퀴드, 크림, 에센스, 계면활성제-함유 클렌징, 오일, 수중유(O/W)형 및 유중수(W/O)형 중 선택되는 어느 하나의 기초 화장료 제형; 스킨; 로션; 아이크림; 수딩젤; 연고; 마스크팩용 제형; 바디워시용 제형; 필링젤; 수중유형 및 유중수형 메이크업베이스; 파운데이션; 스킨커버; 립스틱, 립그로스, 페이스파우더, 투웨이케익, 아이새도, 치크칼라 및 아이브로우 펜슬류 중 선택되는 어느 하나의 색조화장료 제형; 두피용 제형; 중에서 선택되는 어느 하나인 것일 수 있다.On the other hand, the cosmetic composition of the present invention, for example, solution, suspension, emulsion, paste, lotion, gel, water-soluble liquid, cream, essence, surfactant-containing cleansing, oil, oil-in-water (O/W) type and oil Any one of the basic cosmetic formulations selected from heavy water (W/O) type; skin; Lotion; Eye cream; Soothing gel; Ointment; Formulation for mask packs; Body wash formulations; Peeling gel; Water-in-oil and water-in-oil makeup bases; foundation; Skin cover; Lipstick, lip gloss, face powder, two-way cake, eye shadow, cheek color, and eyebrow pencils. Scalp formulations; It may be any one selected from.
또한, 본 발명의 화장료 조성물은 화장 분야에서 통상적으로 사용되는 보조제 예컨대 친수성 또는 친유성 활성제, 보존제, 항산화제, 용매, 방향제, 충전제, 차단제, 안료, 흡취제, 염료 등을 함유할 수 있다. 이들 다양한 보조제의 양은 당해 분야에서 통상적으로 사용되는 양이며, 예컨대 조성물 총 중량에 대해 0.001 내지 30 중량% 이다. 다만, 어떠한 경우라도 보조제 및 그 비율은 본 발명에 따른 화장료 조성물의 바람직한 성질에 악영향을 미치지 않도록 선택될 것이다.In addition, the cosmetic composition of the present invention may contain auxiliaries commonly used in the cosmetic field, such as hydrophilic or lipophilic actives, preservatives, antioxidants, solvents, fragrances, fillers, blockers, pigments, odorants, dyes, and the like. The amount of these various adjuvants is an amount commonly used in the art, for example, 0.001 to 30% by weight based on the total weight of the composition. However, in any case, the auxiliary agent and its ratio will be selected so as not to adversely affect the desirable properties of the cosmetic composition according to the present invention.
한편, 본 발명의 화장료 조성물에 있어서, 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라가칸트, 셀룰로오스 유도체, 폴리에틸렌글리콜, 실리콘, 벤토나이트, 실라카, 탈크 또는 산화아연 등이 이용될 수 있다.On the other hand, in the cosmetic composition of the present invention, when the formulation is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica , Talc or zinc oxide may be used.
또한, 본 발명의 화장료 조성물에 있어서, 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 일례로 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤조에이트, 프로필렌글리콜, 1,3-부틸렌글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌글리콜 또는 소리비탄의 지방산 에스테르가 이용될 수 있다.In addition, in the cosmetic composition of the present invention, when the formulation is a solution or an emulsion, a solvent, a solubilizing agent or an emulsifying agent is used as a carrier component, for example water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, Fatty acid esters of benzoate, propylene glycol, 1,3-butylene glycol oil, glycerol aliphatic esters, polyethylene glycol or sorbitane can be used.
또한 본 발명의 화장료 조성물에 있어서, 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소 결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라가칸트 등이 이용될 수 있다.In the cosmetic composition of the present invention, when the formulation is a suspension, as a carrier component, a liquid diluent such as water, ethanol or propylene glycol, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester The same suspending agents, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tragacanth, etc. can be used.
한편, 본 발명의 화장료 조성물에 있어서, 제형이 파우더 또는 스프레이인 경우에는 담체 성부능로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.On the other hand, in the cosmetic composition of the present invention, when the formulation is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier performance, especially in the case of a spray. Additionally it may include propellants such as chlorofluorohydrocarbon, propane/butane or dimethyl ether.
한편, 본 발명의 화장료 조성물에 있어서, 제형이 계면활성제 함유 클렌징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.On the other hand, in the cosmetic composition of the present invention, when the formulation is a surfactant-containing cleansing, as the carrier component, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, sarcosinate, Fatty acid amide ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
또한, 본 발명의 화장료 조성물에 있어서, 계면활성제 함유 클렌징 제형 또는 계면활성제 비함유 클렌징 제형 또는 비누일 경우에는, 피부에 도포한 후 닦아내거나 떼거나 물로 씻어낼 수도 있다. 일례로, 상기 비누는 액상비누, 가루비누, 고형비누 및 오일비누이며, 상기 계면활성제 함유 클렌징 제형은 클렌징 폼, 클렌징 워터, 클렌징 수건 및 클렌징 팩이며, 상기 계면활성제 비함유 클렌징 제형은 클렌징크림, 클렌징 로션, 클렌징 워터 및 클렌징 젤이며, 이에 한정되는 것은 아니다.In addition, in the cosmetic composition of the present invention, in the case of a surfactant-containing cleansing formulation or a surfactant-free cleansing formulation or soap, after applying to the skin, it may be wiped off, peeled off, or washed with water. In one example, the soap is liquid soap, powdered soap, solid soap and oil soap, and the surfactant-containing cleansing formulation is a cleansing foam, cleansing water, a cleansing towel and a cleansing pack, and the surfactant-free cleansing formulation is a cleansing cream, Cleansing lotions, cleansing water and cleansing gels, but are not limited thereto.
또한, 본 발명의 화장료 조성물은 본 발명 이외의 다른 화장료 조성물과 중복하여 사용할 수 있다. 또한 본 발명에 따른 화장료 조성물은 통상적인 사용방법에 따라 사용될 수 있으며, 사용자의 피부 상태 또는 취향에 따라 그 사용횟수를 달리할 수 있다.In addition, the cosmetic composition of the present invention can be used in combination with other cosmetic compositions other than the present invention. In addition, the cosmetic composition according to the present invention may be used according to a conventional method of use, and the number of times of use may be varied according to a user's skin condition or taste.
이하, 본 발명에 대해 하기 실시예 및 실험예에서 더욱 상세히 설명하고자 한다. 다만, 본 발명의 권리범위가 하기 실시예 및 실험예에만 한정되는 것은 아니고, 이와 등가의 기술적 사상의 변형까지를 모두 포함한다.Hereinafter, the present invention will be described in more detail in the following Examples and Experimental Examples. However, the scope of the present invention is not limited to the following examples and experimental examples, and includes all modifications of equivalent technical ideas.
[실시예 1 : 갯강활추출물의 제조][Example 1: Preparation of Gaetgang Liver Extract]
갯강활 전초를 음건하여 파쇄 후 100g을 10배 가량의 70%(v/v) 에탄올 수용액에 상온에서 3일간 추출하였다. 추출로 얻은 추출물은 와트만(whatman) #5 여과지로 여과하였다. 여과된 추출물을 50℃ 이하에서 감압 농축 및 동결 건조하여 18.6g의 갯강활추출물을 수득하였다. 상기 감압 농축 및 동결 건조물이 0.001 내지 30.0 중량% 함유되도록 정제수, 에탄올, 부틸렌글리콜, 프로필렌글리콜 중에서 선택되는 1종 이상의 용매를 사용하여 분산 및 용해하여 아래 실험에 사용하였다.After crushing the mudguard outpost, 100g was extracted in 10% of 70% (v/v) ethanol aqueous solution for 3 days at room temperature. The extract obtained by extraction was filtered with
[제조예 1 내지 17 : 다양한 추출용매를 이용한 갯강활추출물의 제조][Production Examples 1 to 17: Preparation of Gaetgang Liver Extract Using Various Extraction Solvents]
아래 표 1에 따른 추출용매를 이용하여 상기 실시예 1과 동일하게 갯강활 추출물을 제조하였다. 수득된 최종 추출물의 건조중량은 아래 표 1에 나타내었다.Using the extracting solvent according to Table 1 below, a gaetganglu extract was prepared in the same manner as in Example 1. The dry weight of the final extract obtained is shown in Table 1 below.
[실험예 1 : 갯강활추출물의 항산화 효과 확인][Experimental Example 1: Confirmation of anti-oxidation effect of Gaetgang livestock extract]
본 실험예에서는 상기 실시예 1에서 제조한 갯강활추출물의 항산화효과를 확인하고자 하였다. 항산화 측정법 중 대표적인 DPPH 라디칼은 유기용매에 용해되어 560nm에서 최대 흡광도를 가지는데, 이때 항산화 물질은 DPPH 라디칼을 소거하여 고유의 색을 잃고 황색으로 변화한다.In this experimental example, it was intended to confirm the antioxidant effect of the Gaetgang livestock extract prepared in Example 1. Among the antioxidant measurement methods, a typical DPPH radical is dissolved in an organic solvent and has a maximum absorbance at 560 nm. At this time, the antioxidant substance extinguishes the DPPH radical to lose its own color and turn yellow.
2,2-di(4-tert-octylphenyl)-1-picrylhydrazyl 자유라디칼(Aldrich Chem. Co., MW=618.76) 61.88mg을 메탄올에 용해하여 0.1mM의 DPPH 용액을 제조하였다. 96 well-plate에 0.1mM DPPH 용액 0.15ml와 갯강활추출물 0.15ml를 가하여 교반하고, 25℃에서 10분간 배양을 개시한 후 560nm에서 흡광도(St)를 측정하였다. 시료 용액의 블랭크(Blank)는 상기 0.1mM DPPH 용액 대신 메탄올을 사용하는 것을 제외하고는 상기 흡광도(St)를 측정하는 때와 동일하게 조작하여 흡광도(So)를 측정하였다. 공시험은 상기 갯강활추출물 대신 증류수를 사용하는 것을 제외하고는 상기 흡광도(St)를 측정하는 때와 동일하게 조작하여 흡광도(Bt)를 측정하였다. 공시험의 블랭크(Blank)는 상기 0.1mM DPPH 용액 대신 메탄올을 사용하고 상기 갯강활추출물 대신 증류수를 사용하는 것을 제외하고는 상기 흡광도(St)를 측정하는 때와 동일하게 조작하여 흡광도(Bo)를 측정하였다.61.88mg of 2,2-di(4-tert-octylphenyl)-1-picrylhydrazyl free radical (Aldrich Chem. Co., MW=618.76) was dissolved in methanol to prepare a 0.1 mM DPPH solution. 0.15 ml of 0.1 mM DPPH solution and 0.15 ml of cantilever extract were added to a 96 well-plate, stirred, and incubated at 25° C. for 10 minutes, and absorbance (St) at 560 nm was measured. Blank of the sample solution was measured in the same manner as when measuring the absorbance (St), except that methanol was used instead of the 0.1 mM DPPH solution to measure absorbance (So). In the blank test, the absorbance (Bt) was measured in the same manner as when measuring the absorbance (St), except that distilled water was used instead of the water extract. The blank of the blank test was measured in the same manner as when measuring the absorbance (St), except that methanol was used instead of the 0.1 mM DPPH solution and distilled water was used instead of the cane extract. Did.
자유라디칼 소거율(%)의 결과는 수학식 1에 의해 산출하였으며, 결과는 도 1에 나타내었다.The results of the free radical scavenging rate (%) were calculated by
St : 시료의 자유라디칼 소거 후의 560 nm에서의 흡광도St: absorbance at 560 nm after free radical scavenging of the sample
So : 시료의 자유라디칼 무첨가시 반응 전의 560 nm에서의 흡광도So: Absorbance at 560 nm before reaction when free radicals are not added to the sample
Bt : 공시험용액의 자유라디칼 소거 후의 560 nm에서의 흡광도Bt: Absorbance at 560 nm after free radical scavenging of the blank test solution
Bo : 공시험용액의 자유라디칼 무첨가시 반응 전의 560 nm에서의 흡광도Bo: Absorbance at 560 nm before reaction when free radicals of the test solution are not added
도 1에서 보듯이, 본 발명의 갯강활추출물은 농도 의존적으로 항산화효과가 증가하는 것을 확인하였다. 이에 따라, 본 발명의 갯강활추출물은 우수한 피부 항산화 효과를 발휘하여 피부 노화 억제 효능이 있는 것으로 판단되었다.As shown in Figure 1, it was confirmed that the anti-oxidant effect of the Gaetgang extract of the present invention is concentration-dependent. Accordingly, it was judged that the gaet gang extract of the present invention exerts an excellent skin anti-oxidation effect, thereby inhibiting skin aging.
[실험예 2 : 갯강활추출물의 Claudin-1, Desmoglein-2 발현 효과 확인] [Experimental Example 2: Confirmation of Claudin-1 and Desmoglein-2 expression effects of Gaetgang Liver Extract]
피부 장벽을 구성하는 단백질은 막투과단백질(trans-membrane protein)인 claudin을 비롯하여, desmoglein-2, symplkin 등이 있다. 다양한 단백질 중 특히 claudin의 고리 형태의 구조가 세포 사이의 공간을 채우는 형태로 연결되어, 외부 자극의 세포간 이동 경로를 효율적으로 막을 수 있다. 이러한 밀착연접(tight junction)은 피부 장벽으로서 각질층과 상호 보완적인 기능을 수행하는 것으로 알려져 있다. 본 실험에서는 갯강활추출물의 Claudin-1 및 Desmoglein-2의 발현 효과를 확인하고자 하였다. Proteins that make up the skin barrier include claudin, a trans-membrane protein, and desmoglein-2 and symplkin. Among the various proteins, claudin's ring-shaped structure is connected to fill the space between cells, so it can effectively block the path of movement between cells of external stimuli. This tight junction is known to perform a complementary function with the stratum corneum as a skin barrier. In this experiment, we tried to confirm the effect of the expression of Claudin-1 and Desmoglein-2 of the Gaetgang extract.
인간 유래 각질 형성(HaCaT) 세포를 6 well plate에 3×105 cells/well로 분주하고 37℃, 5% CO2 세포 배양기에서 하루 동안 세포를 안정화시켰다. 미세먼지(fine dust, 50ppm)와 갯강활추출물 10, 30 및 100 ㎍/ml을 각각 처리하고 6시간 반응시킨 후 스크래퍼(scraper)를 이용하여 세포를 수집하였다. 1x 세포 용해 버퍼(cell lysis buffer)를 이용하여 단백질을 분리하고 BCA assay로 단백질을 정량한 후 일정량의 단백질을 10% SDS-PAGE 겔에서 전기영동시켰다. 겔(gel) 상의 분리된 단백질을 PVDF 멤브레인에 전이(transfer)시키고 5% 스킴밀크(skim milk)를 이용하여 1시간 동안 블로킹(blocking)하였다. 1x TTBS 용액으로 3회 세척하고 1차 항체(claudin-1, desmoglein-2, Cell signaling, USA)를 4℃에서 오버나잇(over night) 반응시킨 후, HRP가 결합된 2차 항체를 실온에서 2시간 반응시켰다. 그 후, 1x TTBS로 3회 세척하고 ECL 용액을 반응시켜 Chmi Doc 기기로 밴드를 검출하였다. 베타-액틴(β-actin)의 발현을 기준으로 정량하여 Claudin-1, Desmoglein-2 발현량을 계산하였으며, Image J 1.47 소프트웨어를 이용하여 수치화하였다. 실험결과를 도 2에 나타내었다.Human-derived keratinocytes (HaCaT) cells were dispensed into 3×10 5 cells/well in a 6 well plate, and the cells were stabilized for 1 day in a 37° C., 5% CO 2 cell incubator. Cells were collected using a scraper after treating fine dust (50 ppm) and 10, 30, and 100 µg/ml of Gaet River Extract, respectively, and reacting for 6 hours. Protein was separated using 1x cell lysis buffer, and the protein was quantified by BCA assay, and a certain amount of protein was electrophoresed on a 10% SDS-PAGE gel. The isolated protein on the gel was transferred to the PVDF membrane and blocked for 1 hour using 5% skim milk. After washing 3 times with 1x TTBS solution and reacting the primary antibody (claudin-1, desmoglein-2, Cell signaling, USA) over night at 4° C., the secondary antibody bound with HRP is 2 at room temperature. Time reaction. Thereafter, washing was performed 3 times with 1x TTBS and the ECL solution was reacted to detect a band with a Chmi Doc instrument. Claudin-1 and Desmoglein-2 expression levels were calculated by quantifying the expression of beta-actin, and quantified using Image J 1.47 software. The experimental results are shown in FIG. 2.
도 2에서 보듯이, 본 발명의 갯강활추출물은 미세먼지에 의해 발현량이 감소되는 Claudin-1과 Desmoglein-2의 발현을 증가시켜 피부장벽을 강화효과를 발휘하는 것을 확인하였다. As shown in FIG. 2, it was confirmed that the cannula extract of the present invention exerts a strengthening effect on the skin barrier by increasing the expression of Claudin-1 and Desmoglein-2 in which the expression level is reduced by fine dust.
[실험예 3 : 갯강활추출물의 Nrf2 발현 효과 확인] [Experimental Example 3: Confirmation of Nrf2 expression effect of Gaetgang Liver Extract]
NF-E2 related factor 2(Nrf2)는 산화적 스트레스(미세먼지, 열 등)로부터 인체를 보호하고 생체이물(xenobiotics)의 해독 역할을 하는 phase Ⅱ 효소라 불리는 일련의 단백질을 조절하는 주 조절자로 알려져 있다. 산화적 스트레스가 없는 경우 세포질내 Nrf2는 Keapl 단백질에 결합되어 끊임없이 유비퀴틴화(ubiquitination)되어 분해되므로 그 활성이 억제된다. 반면, 산화적 스트레스가 있는 경우 Nrf2는 Keapl 단백질로부터 유리되어 핵 내로 이동되고 항산화효소 유전자 프로모터 내에 존재하는 항산화반응요소(ARE, antioxidant response element)에 결합하여 항산화효소를 발현시켜 산화적 스트레스를 제거하려 한다. 이러한 역할을 통해 Nrf2는 세포의 항상성 유지에 중요한 역할을 담당하는 것으로 알려져 있다. 본 실험에서는 갯강활추출물의 Nrf2 발현 효과를 확인하고자 하였다.NF-E2 related factor 2 (Nrf2) is a major regulator that regulates a series of proteins called phase II enzymes that protect the human body from oxidative stress (fine dust, heat, etc.) and detoxify xenobiotics. have. In the absence of oxidative stress, Nrf2 in the cytoplasm is bound to the Keapl protein and is constantly ubiquitinated and decomposed, thereby inhibiting its activity. On the other hand, when there is oxidative stress, Nrf2 is released from the Keapl protein, moves into the nucleus, and binds to an antioxidant response element (ARE) present in the antioxidant gene promoter to express antioxidant enzymes to remove oxidative stress. do. Through these roles, Nrf2 is known to play an important role in the maintenance of cell homeostasis. In this experiment, we tried to confirm the effect of Nrf2 expression on Gaetgang extract.
인간 유래 각질 형성(HaCaT) 세포를 6 well plate에 3×105 cells/well로 분주하고 37℃, 5% CO2 세포 배양기에서 하루 동안 세포를 안정화시켰다. 갯강활추출물 3, 10, 30 및 100 ㎍/ml을 각각 처리하고 6시간 반응시킨 후 스크래퍼(scraper)를 이용하여 세포를 수집하였다. 1x 세포 용해 버퍼(cell lysis buffer)를 이용하여 단백질을 분리하고 BCA assay로 단백질을 정량한 후 일정량의 단백질을 10% SDS-PAGE 겔에서 전기영동시켰다. 겔(gel) 상의 분리된 단백질을 PVDF 멤브레인에 전이(transfer)시키고 5% 스킴밀크(skim milk)를 이용하여 1시간 동안 블로킹(blocking)하였다. 1x TTBS 용액으로 3회 세척하고 1차 항체(Nrf2, Cell signaling, USA)를 4℃에서 오버나잇(over night) 반응시킨 후, HRP가 결합된 2차 항체를 실온에서 2시간 반응시켰다. 그 후, 1x TTBS로 3회 세척하고 ECL 용액을 반응시켜 Chmi Doc 기기로 밴드를 검출하였다. 베타-액틴(β-actin)의 발현을 기준으로 정량하여 Nrf2 발현량을 계산하였으며, Image J 1.47 소프트웨어를 이용하여 수치화하였다. 실험결과를 도 3에 나타내었다.Human-derived keratinocytes (HaCaT) cells were dispensed into 3×10 5 cells/well in a 6 well plate, and the cells were stabilized for 1 day in a 37° C., 5% CO 2 cell incubator. Cells were collected using a scraper after treating 3, 10, 30, and 100 µg/ml of the gland extract, and reacting for 6 hours. Protein was separated using 1x cell lysis buffer, and the protein was quantified by BCA assay, and a certain amount of protein was electrophoresed on a 10% SDS-PAGE gel. The isolated protein on the gel was transferred to the PVDF membrane and blocked for 1 hour using 5% skim milk. After washing 3 times with 1x TTBS solution and reacting the primary antibody (Nrf2, Cell signaling, USA) over night at 4° C., the secondary antibody bound with HRP was reacted for 2 hours at room temperature. Thereafter, washing was performed 3 times with 1x TTBS and the ECL solution was reacted to detect a band with a Chmi Doc instrument. The amount of Nrf2 expression was calculated by quantifying the expression of beta-actin, and quantified using Image J 1.47 software. The experimental results are shown in FIG. 3.
도 3에서 보듯이, 본 발명의 갯강활추출물이 Nrf2 발현을 증가시키는 것을 확인하였다. As shown in Figure 3, it was confirmed that the intestinal lumen extract of the present invention increases Nrf2 expression.
[실험예 4 : 갯강활추출물의 MMP-1 발현 억제 효과 확인] [Experimental Example 4: Confirmation of the inhibitory effect of MMP-1 expression on Gaetgang extracts]
본 실험에서는 미세먼지에 의해 발현이 촉진되는 MMP-1에 대하여 갯강활추출물이 미치는 효과를 확인하고자 하였다. In this experiment, we tried to confirm the effect of the Gaet River Liver Extract on MMP-1, whose expression is promoted by fine dust.
인간 피부 섬유아세포(HDFn)를 4×105 cells/well의 농도로 6 well plate에 분주한 후 37℃, 5% CO2 인큐베이터에서 안정화시켰다. 2% FBS가 첨가된 배지로 교환과 동시에 미세먼지(fine dust, 50ppm)와 갯강활추출물 3, 10, 30 및 100 ㎍/ml을 각각 처리하고 6시간 반응시킨 후 스크래퍼(scrape)를 이용하여 세포를 수집하였다. 1x 세포 용해 버퍼(cell lysis buffer)를 이용하여 단백질을 분리하고 BCA assay로 단백질을 정량한 후 일정량의 단백질을 10% SDS-PAGE 겔에서 전기영동시켰다. 겔(Gel) 상의 분리된 단백질을 PVDF 멤브레인에 전이(transfer)시키고 5% 스킴밀크(skim milk)를 이용하여 1시간 블로킹(blocking) 하였다. 1x TTBS 용액으로 3회 세척하고 1차 항체(MMP-1, Santacr, uz)를 4℃에서 오버나잇(over night) 반응시킨 후, HRP가 결합된 2차 항체를 실온에서 2시간 반응시켰다. 그 후, 1x TTBS로 3회 세척하고 ECL 용액을 반응시켜 Chmi Doc 기기로 밴드를 검출하였다. 베타-액틴(β-actin)의 발현을 기준으로 정량하여 MMP-1 발현량을 계산하였으며, Image J 1.47 소프트웨어를 이용하여 수치화하였다. 양성대조군으로 400μM 아데노신(adenosine, 주름기능성고시원료)을 사용하였으며, 실험결과를 도 4에 나타내었다.Human skin fibroblasts (HDFn) were dispensed into 6 well plates at a concentration of 4×10 5 cells/well and stabilized in a 37° C., 5% CO 2 incubator. After replacing with 2% FBS-added medium, fine dust (50ppm) and
도 4에서 보듯이, 본 발명의 갯강활추출물은 미세먼지에 의해 유발되는 MMP-1의 발현을 효과적으로 억제하며 주름 개선 효능이 있음을 확인하였다. As shown in Figure 4, it was confirmed that the Gaetgang extract of the present invention effectively suppresses the expression of MMP-1 caused by fine dust and has an effect of improving wrinkles.
[실험예 5 : 갯강활추출물의 NO 저해율 확인] [Experimental Example 5: Confirmation of NO inhibition rate of Gaet River Liver Extract]
본 실험에서는 미세먼지에 의해 생성되는 NO(nitrogen oxide)에 대하여 갯강활추출물이 미치는 효과를 확인하고자 하였다.In this experiment, we tried to confirm the effect of the Gaet River Liver Extract on NO (nitrogen oxide) produced by fine dust.
마우스 유래 대식세포인 RAW 264.7 세포를 96 well plate에 1×105 cells/well로 분주한 후, 37℃, 5% CO2 세포 배양기에서 하루 동안 세포를 안정화시켰다. 200㎍/ml 농도의 미세먼지(fine dust)와 갯강활추출물 3, 10, 30 및 100 ㎍/ml을 각각 처리한 후 양성대조군으로 NDGA(nordihydroguaiaretic acid)를 5μM 농도로 처리하였다. 24시간 반응시킨 후, 배양 상층액 100㎕를 분리하여 동량의 그리스(Griess) 시약 100㎕를 첨가하여 상온에서 반응시킨 다음 마이크로플레이트 리더(microplate reader)를 이용하여 540nm에서 흡광도를 측정하였다. 산화질소의 농도는 질화나트륨(sodium nitrite, NaNO2)을 사용하여 얻은 표준 직선과 비교하여 산출하였다. 실험 결과는 도 5에 나타내었다.After dispensing RAW 264.7 cells, which are mouse-derived macrophages, into a 96 well plate at 1×10 5 cells/well, cells were stabilized for 1 day in a 37° C., 5% CO 2 cell incubator. After treating fine dust of 200µg/ml and 3, 10, 30, and 100 µg/ml of canine extracts, NDGA (nordihydroguaiaretic acid) was treated as a positive control at a concentration of 5µM. After reacting for 24 hours, 100 µl of the culture supernatant was separated, 100 µl of the same amount of Grease reagent was reacted at room temperature, and absorbance was measured at 540 nm using a microplate reader. The concentration of nitric oxide was calculated by comparison with a standard straight line obtained using sodium nitrite (NaNO 2 ). The experimental results are shown in FIG. 5.
도 5에서 보듯이, 본 발명의 갯강활추출물은 미세먼지에 의해 유발되는 NO를 효과적으로 억제하며 항산화 효능이 있음을 확인하였다.As shown in FIG. 5, it was confirmed that the gaet gang extract of the present invention effectively inhibits NO caused by fine dust and has antioxidant efficacy.
[실시예 2 : 갯강활추출물을 함유하는 화장료 조성물의 제조][Example 2: Preparation of cosmetic composition containing Gaetgang extracts]
아래 표 2와 같은 배합비로 갯강활추출물을 함유하는 화장료 조성물을 제조하였다.A cosmetic composition containing a cane extract was prepared at a mixing ratio as shown in Table 2 below.
A
A
B
B
[실험예 6 : 갯강활추출물을 함유하는 화장료 조성물의 주름 개선 효과 확인] [Experimental Example 6: Confirmation of wrinkle improvement effect of cosmetic composition containing Gaetgang extracts]
본 실험에서는 갯강활추출물을 함유하는 화장료 조성물의 피부 주름 개선 효과에 대한 인체적용시험을 실시하였다.In this experiment, a human body application test was conducted on the effect of improving the skin wrinkles of the cosmetic composition containing the Gaetgang extract.
실험자는 20~35세의 여성 20명을 대상으로 하였으며, 갯강활추출물을 함유하는 화장료 조성물(실시예 2)와 갯강활추출물을 함유하지 않는 화장료 조성물(비교예 1)을 각각 얼굴 오른쪽과 왼쪽에 도포하여 실험을 진행하였다. 하루 1회 도포하여 8주간 사용 후의 각 피검자의 주름 개선 효과를 숙련된 의사의 육안 관찰 및 기기측정(cutometer SEm 575, C+K Electronic Co., Germany)을 통해 평가하였으며, 실험 결과는 아래 표 3에 나타내었다.The experiment was conducted on 20 women aged 20 to 35 years, and the cosmetic composition (Example 2) containing the cannula extract was compared with the cosmetic composition (Comparative Example 1) containing no cannula extract on the right and left sides, respectively. The experiment was carried out by coating. Wrinkle improvement effect of each subject after 8 weeks of application by applying once a day was evaluated by visual observation and instrument measurement (cutometer SEm 575, C+K Electronic Co., Germany) of an experienced doctor, and the experimental results are shown in Table 3 below. It is shown in.
상기 표 2에서 보듯이, 본 발명의 갯강활추출물을 함유하는 화장료 조성물은 75.0%의 높은 주름 개선 효과를 보였다.As shown in Table 2 above, the cosmetic composition containing the Gaetgang Liver Extract of the present invention showed a high wrinkle improvement effect of 75.0%.
[실험예 7 : 갯강활추출물을 함유하는 화장료 조성물의 미세먼지에 의한 염증성 사이토카인 발현량 확인][Experimental Example 7: Confirmation of the expression level of inflammatory cytokines by fine dust in cosmetic compositions containing Gaetgang extracts]
본 실험에서는 갯강활추출물을 함유하는 화장료 조성물이 미세먼지에 의해 유발되는 염증성 사이토카인에 미치는 효과를 확인하고자 하였다.In this experiment, we tried to confirm the effect of the cosmetic composition containing Gaetgang extract on inflammatory cytokines caused by fine dust.
실험자는 20~35세의 여성 20명을 대상으로 하였으며, 미세먼지 도포 전 하박부에 지질흡수 테이프(sebutape)를 부착 후 피부 표면 사이토카인을 수득하였다. 5회 실시하여 각각 1ml PBS 버퍼가 함유된 유리 바이알에 담근 후 1시간 동안 초음파처리(sonicator)한 뒤 사이토카인 함량을 측정하였다.The experimenter was conducted on 20 women aged 20 to 35 years, and a lipid absorbing tape (sebutape) was attached to the lower part of the skin before applying fine dust to obtain cytokines on the skin surface. After conducting 5 times, each was immersed in a glass vial containing 1 ml PBS buffer, sonicated for 1 hour, and then the cytokine content was measured.
미세먼지(500 ppm)를 미네랄 오일과 1:1로 혼합한 후 하박부에 처리하고 갯강활추출물을 함유하는 화장료 조성물(실시예2)과 갯강활추출물을 함유하지 않는 화장료 조성물(비교예 1)을 각각 도포하여 지질흡수 테이프(sebutape)를 붙이고 24시간 후 제거하여 상기와 동일한 방법으로 사이토카인을 수득하였다.After mixing the fine dust (500 ppm) 1:1 with mineral oil, treat it in the lower extremity and apply a cosmetic composition (Example 2) and a cosmetic composition that does not contain a gastrointestinal activity extract (Comparative Example 1). Each was coated with a lipid absorbing tape (sebutape) and removed after 24 hours to obtain cytokines in the same manner as above.
ELISA 키트를 이용하여 사이토카인 함량을 정량하고, 단백질 정량 키트를 이용하여 총 단백질량을 정량한 후 사이토카인 함량을 총 단백질 함량으로 보정하여 결과를 분석하였다. 실험 결과를 도 6에 나타내었다.The cytokine content was quantified using the ELISA kit, the total protein amount was quantified using the protein quantification kit, and the result was analyzed by correcting the cytokine content to the total protein content. The experimental results are shown in FIG. 6.
도 6에서 보듯이, 본 발명의 갯강활추출물을 함유하는 화장료 조성물은 미세먼지에 의해 유발되는 염증성 사이토카인인 TNF-α와 IL-8의 발현량을 크게 감소시키는 것을 확인하였다.As shown in Figure 6, it was confirmed that the cosmetic composition containing the cannula extract of the present invention significantly reduces the expression levels of inflammatory cytokines TNF-α and IL-8 caused by fine dust.
Claims (10)
미세먼지에 의해 감소된 Claudin-1 및 Desmoglein-2의 발현을 증가시키는 것을 특징으로 하는 미세먼지에 의해 손상된 피부장벽강화용 화장료 조성물.
Angelica japonica contains 70% (v/v) ethanol extract,
A cosmetic composition for strengthening skin barrier damaged by fine dust, characterized by increasing the expression of Claudin-1 and Desmoglein-2 reduced by fine dust.
미세먼지에 의해 유발된 MMP-1의 발현을 억제하는 것을 특징으로 하는 미세먼지에 의해 유발된 피부주름개선용 화장료 조성물.
Angelica japonica contains 70% (v/v) ethanol extract,
A cosmetic composition for improving skin wrinkles caused by fine dust, characterized by inhibiting the expression of MMP-1 caused by fine dust.
상기 갯강활 70%(v/v) 에탄올추출물은,
화장료 조성물 전체 중량에 대하여 0.001~30 중량%로 함유하는 것을 특징으로 하는 화장료 조성물.
The method of claim 3 or 7,
70% (v/v) ethanol extract of the swelling,
Cosmetic composition comprising 0.001 to 30% by weight relative to the total weight of the cosmetic composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190131636A KR102123645B1 (en) | 2019-10-22 | 2019-10-22 | Cosmetic composition with Angelica japonica extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020190131636A KR102123645B1 (en) | 2019-10-22 | 2019-10-22 | Cosmetic composition with Angelica japonica extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR102123645B1 true KR102123645B1 (en) | 2020-06-18 |
Family
ID=71143420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020190131636A Active KR102123645B1 (en) | 2019-10-22 | 2019-10-22 | Cosmetic composition with Angelica japonica extract |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102123645B1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230001247A (en) | 2021-06-28 | 2023-01-04 | 청담씨디씨제이앤팜 유한책임회사 | Cosmetic composition for allevation of skin irritation from fine dust with the extract of spinach and beet |
| KR102692059B1 (en) * | 2023-12-28 | 2024-08-06 | (주)엔비바이오컴퍼니 | A cosmetic composition for anti-oxidation, anti-inflammation, protecting effect of skin cell from fine dust, and skin soothing comprising nano liposome comprising artemisia capillaris extract, angelica japonica extract, and imperata cylindrica extract |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0176415B1 (en) | 1995-07-21 | 1999-05-15 | 김은영 | Farnesyl transferase inhibitor and derivative, process for the preparation thereof and composition containing same |
| KR20130047778A (en) * | 2011-10-25 | 2013-05-09 | (주)아모레퍼시픽 | Fermentation method using medicinal flower and skin external composition containing fermented extract by the method |
| JP5312727B2 (en) * | 2005-03-07 | 2013-10-09 | アクセス ビジネス グループ インターナショナル エルエルシー | A plant-based formulation for improving the moisture retention, texture and appearance of the skin |
| KR20160003915A (en) * | 2014-07-01 | 2016-01-12 | 주식회사 엘지생활건강 | Cosmetic composition for enhancing skin elasticity or improving skin wrinkle containing herb extracts |
| KR101956886B1 (en) | 2017-08-16 | 2019-03-11 | 주식회사 사임당화장품 | Cosmetic composition for ameliorating skin damaged by fine dust or yellow dust |
| JP2019043915A (en) * | 2017-09-06 | 2019-03-22 | 株式会社ノエビア | Skin external preparation |
-
2019
- 2019-10-22 KR KR1020190131636A patent/KR102123645B1/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0176415B1 (en) | 1995-07-21 | 1999-05-15 | 김은영 | Farnesyl transferase inhibitor and derivative, process for the preparation thereof and composition containing same |
| JP5312727B2 (en) * | 2005-03-07 | 2013-10-09 | アクセス ビジネス グループ インターナショナル エルエルシー | A plant-based formulation for improving the moisture retention, texture and appearance of the skin |
| KR20130047778A (en) * | 2011-10-25 | 2013-05-09 | (주)아모레퍼시픽 | Fermentation method using medicinal flower and skin external composition containing fermented extract by the method |
| KR20160003915A (en) * | 2014-07-01 | 2016-01-12 | 주식회사 엘지생활건강 | Cosmetic composition for enhancing skin elasticity or improving skin wrinkle containing herb extracts |
| KR101956886B1 (en) | 2017-08-16 | 2019-03-11 | 주식회사 사임당화장품 | Cosmetic composition for ameliorating skin damaged by fine dust or yellow dust |
| JP2019043915A (en) * | 2017-09-06 | 2019-03-22 | 株式会社ノエビア | Skin external preparation |
Non-Patent Citations (1)
| Title |
|---|
| Eun-Jin Yang et al., In vitro screening of Korean halophytes for cosmeceutical ingredients, International Journal of ChemTech Research, Vol.9, No.08, pp.541-547 (2016.)* * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230001247A (en) | 2021-06-28 | 2023-01-04 | 청담씨디씨제이앤팜 유한책임회사 | Cosmetic composition for allevation of skin irritation from fine dust with the extract of spinach and beet |
| KR102692059B1 (en) * | 2023-12-28 | 2024-08-06 | (주)엔비바이오컴퍼니 | A cosmetic composition for anti-oxidation, anti-inflammation, protecting effect of skin cell from fine dust, and skin soothing comprising nano liposome comprising artemisia capillaris extract, angelica japonica extract, and imperata cylindrica extract |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100858629B1 (en) | Cosmetic composition for skin vitality enhancement containing baekbaek extract, haesong extract and baeksong extract as active ingredients | |
| KR102500924B1 (en) | Baby cosmetic composition for skin moisturizing | |
| KR102073945B1 (en) | Cosmetic composition for improvement of skin itching and moisturizing with the extract of Corydalis platycarpa | |
| KR101176528B1 (en) | Cosmetic composition comprising the extract of salvia plebeia as active ingredient | |
| KR102123645B1 (en) | Cosmetic composition with Angelica japonica extract | |
| KR102099783B1 (en) | Cosmetic Composition Containing The Mixed Extract of Dracaena fragrans and Trifolium repens | |
| KR101781466B1 (en) | Antioxidant composition for skin external application comprising nelumbo nucifera flowers extract and prunus mume fruits extract | |
| KR101860109B1 (en) | Skin external composition containing floral ginsenoside | |
| KR100874115B1 (en) | Cosmetic composition containing thyme extract as an active ingredient | |
| KR100920896B1 (en) | Cosmetic composition for skin whitening containing blue lotus and tetrahydrocurcumin as an active ingredient | |
| KR102026399B1 (en) | Cosmetic composition for skin Humectant comprising Opuntia Ficus-Indica fruit extract and mixed compound of panthenol, hyaluronic acid and betaine | |
| KR102087976B1 (en) | Cosmetic composition containing extract of fraxinus rhynchophylla for improving skin wrinkle | |
| KR102278167B1 (en) | A cosmetic composition having prevention of lipid peroxidation, improved damaged skin and soothing effect on redness of skin | |
| KR101781545B1 (en) | A cosmetic composition for skin whitening comprising the extract of saccharina japonica as active ingredient | |
| KR20180081327A (en) | Composition for skin conditioning comprising Adenophora Stricta extract | |
| KR102066384B1 (en) | A cosmetic composition having excellent skin barrier improvement with filaggrin activity | |
| KR101877803B1 (en) | Skin external composition containing floral ginsenoside | |
| KR102031288B1 (en) | A cosmetic composition comprising cabbage cultiva rfermented extract | |
| JP6915048B2 (en) | Use of Arbutus Uned fruit extract as a cosmetic | |
| KR101558186B1 (en) | Cosmetic composition containing fox bead extract | |
| KR100638053B1 (en) | Cosmetic composition for alleviating skin irritation containing Soru-Jin extract as an active ingredient | |
| KR101363029B1 (en) | The cosmetic composition for anti-oxident and anti-aging of the skin comprising the Gelidium amansii, Undaria pinnatifida, wheat bud and Monarda horsemint | |
| KR100891387B1 (en) | Cosmetic composition containing hydroxy extract as an active ingredient | |
| KR20090056522A (en) | Cosmetic composition having a free radical scavenging effect containing Kishil, Woncho, herbaceous, sperm and Phalanx extract as active ingredients | |
| KR20070096279A (en) | Cosmetic composition containing the extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20191022 |
|
| PA0201 | Request for examination | ||
| PA0302 | Request for accelerated examination |
Patent event date: 20191108 Patent event code: PA03022R01D Comment text: Request for Accelerated Examination Patent event date: 20191022 Patent event code: PA03021R01I Comment text: Patent Application |
|
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20200108 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20200518 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20200610 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20200611 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |